Case | Study number | Number requiring critical care | Number of maternal deaths | Type of arterial thrombotic events | Type of venous thrombotic events 1 = inferior vena cava 2 = pulmonary embolism 3 = DVT | Number symptomatic | Diagnosis of event made antenatally (1) or postnatally (2) | Number receiving thromboprophylaxis prior to VTE event | If thromboprophylaxis reported, what type and what dose? | D-dimer measurement (micrograms/ml normal = < 0.5) | Risk factors: PET = 1, smoker = 2, FHx VTE = 3, Age > 35 = 4, IVF = 5, twins = 6, parity > 3 = 7, BMI > 30 = 8 |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 65 | 1 | 0 | 0 | 1 |  | 1 | 1 | “therapeutic anticoagulation” | Not given | 7 |
2 | 87 | 1 | 0 | 0a | 0 |  | 1 | 1 | enoxaparin 40 mg subcutaneously daily. BMI 41.5 | 0.57–2.82 | 4,8 |
3 | UKOSS (107) | 1 | 1 | Basilar artery thrombosis | 2 | 1 “Deteriorating respiratory function” | 2 | 1 | Enoxaparin (prophylactic dose) | Not given | 8, |
4 | 141 | Â | 1 | 0 | 2 | Â | Â | Â | Â | Â | Â |
5 | 159 | 1 | 0 | 0 | 0b | 0 | 1 | 1 | Lovenox 40 mg daily | Not given | 4,5 |